Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v54,p587)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tonelli, J.
Right arrow Articles by Hawkins, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tonelli, J.
Right arrow Articles by Hawkins, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:1621-1629, 2004
© 2004 by the American Diabetes Association, Inc.

Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes

Julia Tonelli1, Weijie Li1, Preeti Kishore1, Utpal B. Pajvani2, Elize Kwon1, Charles Weaver1, Philipp E. Scherer1,2, and Meredith Hawkins1

1 Department of Medicine, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York
2 Department of Cell Biology, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York

Whereas thiazolidinediones (TZDs) are known to rapidly improve insulin action in animals, short durations of TZD therapy have never been studied in humans. Among the many known actions of TZDs, increased circulating levels of the high molecular weight (HMW) multimer of adiponectin may be an important insulin-sensitizing mechanism. We examined the effects of only 21 days of 45 mg of pioglitazone (P+) versus placebo (P–) in nine subjects with type 2 diabetes (HbA1c, 10.9 ± 0.6%; BMI, 31.9 ± 1.5 kg/m2). Total adiponectin levels increased by approximately twofold in P+ in association with increased adipose tissue gene expression. However, plasma free fatty acid and glucose levels were unchanged, and there were only minimal changes in other "adipokines." Glucose fluxes ([3-3H]glucose infusion) were measured during 6-h euglycemic (5 mmol/l) "pancreatic clamp" studies (somatostatin/glucagon/growth hormone) with stepped insulin levels. Pioglitazone induced marked decreases in endogenous glucose production (P+ = 0.9 ± 0.1 vs. P– = 1.7 ± 0.3 mg · kg–1 · min–1; P < 0.05) at physiologic hyperinsulinemia (~50 µU/ml), which was highly correlated with an increased ratio of HMW adiponectin/total levels (r2 = 0.90). Maximal insulin stimulation (~400 µU/ml) revealed pioglitazone-associated increases in glucose uptake (P+ = 10.5 ± 0.9 vs. P– = 8.9 ± 0.8 mg · kg–1 · min–1; P < 0.05), which did not correlate with HMW or total adiponectin levels. Thus, only 21 days of pioglitazone therapy improved insulin action in humans with type 2 diabetes. Increased abundance of the HMW adiponectin multimer may contribute to the hepatic insulin-sensitizing effects of these agents.

Address correspondence and reprint requests to Meredith Hawkins, MD, Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461. E-mail: hawkins{at}aecom.yu.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza
Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
Diabetes, January 1, 2008; 57(1): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Basu, U. B. Pajvani, R. A. Rizza, and P. E. Scherer
Selective Downregulation of the High Molecular Weight Form of Adiponectin in Hyperinsulinemia and in Type 2 Diabetes: Differential Regulation From Nondiabetic Subjects
Diabetes, August 1, 2007; 56(8): 2174 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Z. V. Wang, T. D. Schraw, J.-Y. Kim, T. Khan, M. W. Rajala, A. Follenzi, and P. E. Scherer
Secretion of the Adipocyte-Specific Secretory Protein Adiponectin Critically Depends on Thiol-Mediated Protein Retention
Mol. Cell. Biol., May 15, 2007; 27(10): 3716 - 3731.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. J. Wake, R. H. Stimson, G. D. Tan, N. Z. M. Homer, R. Andrew, F. Karpe, and B. R. Walker
Effects of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} Agonists on 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Subcutaneous Adipose Tissue in Men
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1848 - 1856.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
W. Li, J. Tonelli, P. Kishore, R. Owen, E. Goodman, P. E. Scherer, and M. Hawkins
Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1301 - E1307.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Wiecek, M. Adamczak, and J. Chudek
Adiponectin--an adipokine with unique metabolic properties
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 981 - 988.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Cnop, J. Vidal, R. L. Hull, K. M. Utzschneider, D. B. Carr, T. Schraw, P. E. Scherer, E. J. Boyko, W. Y. Fujimoto, and S. E. Kahn
Progressive Loss of {beta}-Cell Function Leads to Worsening Glucose Tolerance in First-Degree Relatives of Subjects With Type 2 Diabetes
Diabetes Care, March 1, 2007; 30(3): 677 - 682.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Bluher, A. M. Brennan, T. Kelesidis, J. Kratzsch, M. Fasshauer, S. Kralisch, C. J. Williams, and C. S. Mantzoros
Total and High-Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative evaluation of three assays
Diabetes Care, February 1, 2007; 30(2): 280 - 285.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Kolak, H. Yki-Jarvinen, K. Kannisto, M. Tiikkainen, A. Hamsten, P. Eriksson, and R. M. Fisher
Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissue in Vivo in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 720 - 724.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
V. M. Nayagam, X. Wang, Y. C. Tan, A. Poulsen, K. C. Goh, T. Ng, H. Wang, H. Y. Song, B. Ni, M. Entzeroth, et al.
SIRT1 Modulating Compounds from High-Throughput Screening as Anti-Inflammatory and Insulin-Sensitizing Agents
J Biomol Screen, December 1, 2006; 11(8): 959 - 967.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. M. Bodles, A. Banga, N. Rasouli, F. Ono, P. A. Kern, and R. J. Owens
Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1100 - E1105.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. J. Hernandez-Morante, F. Milagro, J. A. Gabaldon, J. A. Martinez, S. Zamora, and M. Garaulet
Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans.
Eur. J. Endocrinol., October 1, 2006; 155(4): 593 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Gastaldelli, Y. Miyazaki, A. Mahankali, R. Berria, M. Pettiti, E. Buzzigoli, E. Ferrannini, and R. A. DeFronzo
The Effect of Pioglitazone on the Liver: Role of adiponectin
Diabetes Care, October 1, 2006; 29(10): 2275 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Nakashima, N. Kamei, K. Yamane, S. Nakanishi, A. Nakashima, and N. Kohno
Decreased Total and High Molecular Weight Adiponectin Are Independent Risk Factors for the Development of Type 2 Diabetes in Japanese-Americans
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3873 - 3877.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Shadid, C. D. A. Stehouwer, and M. D. Jensen
Diet/Exercise Versus Pioglitazone: Effects of Insulin Sensitization with Decreasing or Increasing Fat Mass on Adipokines and Inflammatory Markers
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3418 - 3425.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Bergeron, J. Yao, J. W. Woods, E. I. Zycband, C. Liu, Z. Li, A. Adams, J. P. Berger, B. B. Zhang, D. E. Moller, et al.
Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPAR{gamma} Agonism
Endocrinology, September 1, 2006; 147(9): 4252 - 4262.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. A. Richards, T. Stephens, H. K. Charlton, A. Jones, G. A. Macdonald, J. B. Prins, and J. P. Whitehead
Adiponectin Multimerization Is Dependent on Conserved Lysines in the Collagenous Domain: Evidence for Regulation of Multimerization by Alterations in Posttranslational Modifications
Mol. Endocrinol., July 1, 2006; 20(7): 1673 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Aso, R. Yamamoto, S. Wakabayashi, T. Uchida, K. Takayanagi, K. Takebayashi, T. Okuno, T. Inoue, K. Node, T. Tobe, et al.
Comparison of Serum High-Molecular Weight (HMW) Adiponectin With Total Adiponectin Concentrations in Type 2 Diabetic Patients With Coronary Artery Disease Using a Novel Enzyme-Linked Immunosorbent Assay to Detect HMW Adiponectin.
Diabetes, July 1, 2006; 55(7): 1954 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Wang, K. S. L. Lam, L. Chan, K. W. Chan, J. B. B. Lam, M. C. Lam, R. C. L. Hoo, W. W. N. Mak, G. J. S. Cooper, and A. Xu
Post-translational Modifications of the Four Conserved Lysine Residues within the Collagenous Domain of Adiponectin Are Required for the Formation of Its High Molecular Weight Oligomeric Complex
J. Biol. Chem., June 16, 2006; 281(24): 16391 - 16400.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Basu, M. D. Jensen, F. McCann, D. Mukhopadhyay, M. J. Joyner, and R. A. Rizza
Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.
Diabetes Care, March 1, 2006; 29(3): 510 - 514.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Santini, D. Ciociaro, R. A. DeFronzo, and E. Ferrannini
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 806 - 812.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. S. Hermann, W. Li, H. Dominguez, N. Ihlemann, C. Rask-Madsen, A. Major-Pedersen, D. B. Nielsen, K. W. Hansen, M. Hawkins, L. Kober, et al.
Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1001 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Gut and Adipocyte Peptides
Diabetes Care, February 1, 2006; 29(2): 450 - 456.
[Full Text] [PDF]

Home page
 DiabetesHome page
C. Lara-Castro, N. Luo, P. Wallace, R. L. Klein, and W. T. Garvey
Adiponectin Multimeric Complexes and the Metabolic Syndrome Trait Cluster
Diabetes, January 1, 2006; 55(1): 249 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. J. Wilkes, M. T. A. Nguyen, G. K. Bandyopadhyay, E. Nelson, and J. M. Olefsky
Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats
Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1015 - E1022.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Li, P. A. Hansen, L. Xi, R. A. S. Chandraratna, and C. F. Burant
Distinct Mechanisms of Glucose Lowering by Specific Agonists for Peroxisomal Proliferator Activated Receptor {gamma} and Retinoic Acid X Receptors
J. Biol. Chem., November 18, 2005; 280(46): 38317 - 38327.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Dhindsa, D. Tripathy, N. Sanalkumar, S. Ravishankar, H. Ghanim, A. Aljada, and P. Dandona
Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5058 - 5063.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. Kadowaki and T. Yamauchi
Adiponectin and Adiponectin Receptors
Endocr. Rev., May 1, 2005; 26(3): 439 - 451.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.